Ideas

Hyperbaric oxygen (HBO) therapy for cardiac hypertrophy and fibrosis: Hyperbaric oxygen (HBO) therapy decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via up regulation of its target gene, 30/November/2020, 10. 40 pm

Hyperbaric oxygen (HBO) therapy for cardiac hypertrophy and fibrosis: Hyperbaric oxygen (HBO) therapy decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via up regulation of its target gene, 30/November/2020, 10. 40 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:   A recent study from the Institute of Pharmacology and Toxicology, Technical University Munich (TUM), 80802, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich…

read more

Krebs cycle–derived immunometabolite itaconate based therapy for COVID-19/SARS-COV-2 and other infectious diseases: 4-Octyl Itaconate, a cell-permeable derivative derived from the TCA cycle metabolite Aconitate, inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, Foot and Mouth disease, ADV, respiratory syncytial, Sindbis, and SFV viruses and others by increasing the levels of NRF2, IFN (Interferon)-alpha/alpha-2/beta/gamma/lamda, interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides and decreasing the expression of inflammatory cytokines, 19/November/2020, 11.43 am

Krebs cycle–derived immunometabolite itaconate based therapy for COVID-19/SARS-COV-2 and other infectious diseases: 4-Octyl Itaconate, a cell-permeable derivative derived from the TCA cycle metabolite Aconitate, inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, Foot and Mouth disease, ADV, respiratory syncytial, Sindbis, and SFV viruses and others by increasing the levels of NRF2, IFN (Interferon)-alpha/alpha-2/beta/gamma/lamda, interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides and decreasing the expression of inflammatory cytokines, 19/November/2020, 11.43 am 1280 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, Charlestown, MA 02129, USA shows that “The IFITM proteins…

read more

PTC299-based therapy for COVID-19/SARS-COV-2 and other infectious diseases: PTC299, an anti-cancer drug, inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial, Sindbis, and SFV viruses and others by increasing the levels of IFN (Interferon)-alpha/alpha-2/beta/gamma/lamda, interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides and decreasing the expression of inflammatory cytokines 24/October/2020, 9.39 am

PTC299-based therapy for COVID-19/SARS-COV-2 and other infectious diseases: PTC299, an anti-cancer drug, inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial, Sindbis, and SFV viruses and others by increasing the levels of IFN (Interferon)-alpha/alpha-2/beta/gamma/lamda, interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides and decreasing the expression of inflammatory cytokines 24/October/2020, 9.39 am 1280 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, Charlestown, MA 02129, USA shows that “The IFITM proteins…

read more

Repurposing the tuberculosis BCG vaccine into a Prophylactic COVID-19 vaccine: Recombinant BCG85C5 vaccine inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, respiratory syncytial, Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 30/September/2020, 23.58

Repurposing the tuberculosis BCG vaccine into a Prophylactic COVID-19 vaccine: Recombinant BCG85C5 vaccine inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, respiratory syncytial, Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 30/September/2020, 23.58 1280 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, Charlestown, MA 02129, USA shows that “The IFITM proteins…

read more

Honey-based therapy for COVID-19 and other infectious diseases: Manuka honey-based therapy for SARS-COV-2: Manuka honey, can be obtained from the nectar of Manuka tree (Leptospermum scoparium), inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial, Sindbis, and SFV viruses and others by increasing the levels of IFN (Interferon)-alpah/alpha-2/beta/gamma/lamda, interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides 24/August/2020, 12.07 am

Honey-based therapy for COVID-19 and other infectious diseases: Manuka honey-based therapy for SARS-COV-2: Manuka honey, can be obtained from the nectar of Manuka tree (Leptospermum scoparium), inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial, Sindbis, and SFV viruses and others by increasing the levels of IFN (Interferon)-alpah/alpha-2/beta/gamma/lamda, interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides 24/August/2020, 12.07 am 1280 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, Charlestown, MA 02129, USA shows that “The IFITM proteins…

read more

Salidorside-based regenerative cardiovascular therapy: Molecular mechanistic insight into how Salidorside protects against and promotes functional recovery after Myocardial Infarction: Salidorside inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte proliferation, regeneration and survival after myocardial infarction, via up-regulation of its target gene, 16/August/2020, 4.03 pm

Salidorside-based regenerative cardiovascular therapy: Molecular mechanistic insight into how Salidorside protects against and promotes functional recovery after Myocardial Infarction: Salidorside inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte proliferation, regeneration and survival after myocardial infarction, via up-regulation of its target gene, 16/August/2020, 4.03 pm 960 720 Dr Boomi's Genom-2-Discovery Center

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of of the journal Nature,  by Profs. Stefanie…

read more